Mail

BHVN - Biohaven Pharmaceutical Holding Company Ltd.

NYSE - Nasdaq Real Time Price. Currency in USD

49.27

-0.83 (-1.66%)

As of 2:20PM EDT. Market open.

Stock chart is not supported by your current browser

Previous Close	50.10
Open	50.28
Bid	48.85 x 800
Ask	48.95 x 1100
Day's Range	47.94 - 50.44
52 Week Range	16.50 - 50.65
Volume	485,667
Avg. Volume	461,340

Market Cap	2.181B
Beta (3Y Monthly)	N/A
PE Ratio (TTM)	N/A
EPS (TTM)	-6.15
Earnings Date	N/A
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	59.17

Trade prices are not sourced from all markets

All

News

Press Releases

PR Newswire7 hours ago
Biohaven Secures Priority Review Voucher (PRV) To Expedite Regulatory Review Of Rimegepant Zydis ODT New Drug Application
-Rimegepant Zydis orally disintegrating tablet (ODT) is Biohaven's lead oral CGRP receptor antagonist drug candidate from its NOJECTION™ migraine platform -A priority review voucher (PRV) entitles the ...
GuruFocus.com4 days ago
Biohaven Pharmaceutical Holding Co Ltd (BHVN) CEO Vlad Coric Sold $5 million of Shares
CEO of Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Vlad Coric sold 100,000 shares of BHVN on 03/14/2019 at an average price of $50.09 a share.
Simply Wall St.4 days ago
Has Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) Got Enough Cash?
Mid-caps stocks, like Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) with a market capitalization of US$2.2b, aren’t the focus of most investors who prefer to direct their investments towards either large-capRead More...
PR Newswire4 days ago
Biohaven Enrolls First Patient In Phase 3 Spinocerebellar Ataxia Clinical Trial Of Troriluzole
NEW HAVEN, Conn., March 14, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, today announced that it has enrolled the first patient in a Phase 3 clinical trial assessing the efficacy and safety of troriluzole in Spinocerebellar Ataxia (SCA). Biohaven expects to enroll approximately 230 patients in this randomized, double-blind, placebo-controlled trial across approximately 22 sites in the United States.
PR Newswire5 days ago
Biohaven Announces Completion of Pre-NDA Meeting With FDA for Oral CGRP Receptor Antagonist Rimegepant
NEW HAVEN, Conn., March 13, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, including rare disorders, today announced that the Company concluded its pre-New Drug Application ("NDA") meetings with the U.S. Food and Drug Administration ("FDA") for rimegepant Zydis® ODT (orally dissolving tablet) and tablet formulations for the acute treatment of migraine. The purpose of the meeting was to discuss the proposed NDA and to confirm the clinical, non-clinical, and chemistry, manufacturing and controls (CMC) requirements for the Company's NDA submission.
GlobeNewswire13 days ago
Factors of Influence in 2019, Key Indicators and Opportunity within Expedia Group, Lumentum, Patterson Companies, Allscripts Healthcare Solutions, AtriCure, and Biohaven Pharmaceutical Holding — New Research Emphasizes Economic Growth
NEW YORK, March 05, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
PR Newswire18 days ago
Biohaven Pharmaceuticals Reports Fourth Quarter And Full Year 2018 Financial And Recent Business Results
-Positioned to submit New Drug Applications (NDA) for rimegepant Zydis ODT and tablet formulations for the acute treatment of migraine in 2Q2019 -Anticipate completion of Phase 3 trial of rimegepant preventive ...
Zacks25 days ago
What Makes Biohaven Pharmaceutical Holding Company Ltd. (BHVN) a Strong Momentum Stock: Buy Now?
Does Biohaven Pharmaceutical Holding Company Ltd. (BHVN) have what it takes to be a top stock pick for momentum investors? Let's find out.
PR Newswire26 days ago
Biohaven Enrolls First Patient In Phase 3 Generalized Anxiety Disorder (GAD) Trial Of Troriluzole
NEW HAVEN, Conn., Feb. 20, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neuropsychiatric diseases, today announced that it has enrolled its first patient in a Phase 3 clinical trial assessing the efficacy and safety of troriluzole in generalized anxiety disorder (GAD).
PR Newswire27 days ago
Biohaven's Verdiperstat Receives Orphan Drug Designation From FDA For Multiple System Atrophy
NEW HAVEN, Conn., Feb. 19, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) ("Biohaven") announced today that it received orphan drug designation from the U.S. Food and Drug Administration (FDA) for its product candidate verdiperstat (previously BHV-3241), a novel myeloperoxidase (MPO) inhibitor, for the treatment of multiple system atrophy (MSA).
PR Newswirelast month
Biohaven Achieves Targeted Therapeutic Exposures of BHV-3500, a Third-Generation Small Molecule CGRP Receptor Antagonist
Phase 2 Efficacy Trial Start Planned for Second Quarter 2019 - BHV-3500 is the first CGRP receptor antagonist drug candidate to be administered in an intranasal (IN) formulation and Biohaven's second drug ...
Benzinga2 months ago
The Daily Biotech Pulse: PTC Therapeutics, Select Biosciences Offering, Unity Biotech Expands Early-Stage Osteoarthritis Drug Study
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peak (Biotech stocks hitting 52-week highs on Jan. 22) Veracyte Inc (NASDAQ: VCYT ) Down In The Dumps (Biotech ...
PR Newswire2 months ago
Biohaven Receives FDA May Proceed Letter For Phase 3 Clinical Trial Of BHV-3241 For Multiple System Atrophy
NEW HAVEN, Conn., Jan. 23, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) ("Biohaven") announced today the U.S. Food and Drug Administration (FDA) has notified the Company that it may proceed with its clinical investigation of BHV-3241, a novel myeloperoxidase (MPO) inhibitor, which Biohaven is developing as a potential treatment for multiple system atrophy (MSA). The FDA May Proceed Letter was received following Biohaven's reactivation of the investigational new drug (IND) application initially filed by AstraZeneca prior to licensing the compound to Biohaven.
PR Newswire2 months ago
Biohaven Announces Acceptance Of Investigational New Drug (IND) Filing For Rimegepant In China
NEW HAVEN, Conn. and SHANGHAI, Jan. 7, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) ("Biohaven") and its wholly-owned Asia-Pacific subsidiary company, BioShin, announced today the National Medical Products Administration ("NMPA") (formerly, the China FDA) has accepted the investigational new drug (IND) application for rimegepant, Biohaven's lead oral calcitonin gene-related peptide (CGRP) receptor antagonist product candidate, for the treatment of migraine. CGRP receptor antagonists represent a novel class of drug candidates for the treatment of migraine and are the first new class for the treatment of migraine in over 25 years.
GlobeNewswire2 months ago
Detailed Research: Economic Perspectives on Biohaven Pharmaceutical Holding, Air Transport Services Group, Pattern Energy Group, First Solar, Limelight Networks, and Adamis Pharmaceuticals — What Drives Growth in Today's Competitive Landscape
NEW YORK, Jan. 03, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
PR Newswire3 months ago
Biohaven Announces Closing Of $144M Public Offering Of Common Shares, Including Full Exercise Of Underwriters' Option To Purchase Additional Shares
NEW HAVEN, Conn. , Dec. 17, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven" or the "Company"), a clinical‑stage biopharmaceutical company ...
PR Newswire3 months ago
Biohaven Announces Pricing of Public Offering of Common Shares
NEW HAVEN, Conn. , Dec. 12, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinical‑stage biopharmaceutical company with a portfolio of innovative, late‑stage product ...
PR Newswire3 months ago
Biohaven Announces Proposed Public Offering of Common Shares
NEW HAVEN, Conn., Dec. 10, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN), a clinical‑stage biopharmaceutical company with a portfolio of innovative, late‑stage product candidates targeting neurological diseases, including rare disorders, today announced that it has commenced an underwritten public offering of 3,000,000 of its common shares.
PR Newswire3 months ago
Biohaven Announces Positive Results from Ongoing Rimegepant Long-Term Safety Study
NEW HAVEN, Conn., Dec. 10, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) today announced initial positive results from its ongoing long-term, open-label safety study of its oral calcitonin gene-related peptide (CGRP) receptor antagonist, rimegepant, for the acute treatment of migraine. Based upon this interim analysis (database cutoff of November 21, 2018) of Study BHV3000-201 (NCT03266588 or "Study 201") it appears that rimegepant may be safe and well tolerated with long-term dosing in patients with migraine.
PR Newswire3 months ago
Biohaven Delivers Positive Phase 3 Results with Rimegepant Zydis® Orally Dissolving Tablet (ODT): Rapid and Lasting Benefit for the Acute Treatment of Migraine
NEW HAVEN, Conn., Dec. 3, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) today announced positive topline results from a randomized, controlled Phase 3 clinical trial (BHV3000-303 or Study 303) evaluating the efficacy and safety of its Zydis® orally dissolving tablet (ODT) formulation of rimegepant, an oral calcitonin gene-related peptide (CGRP) receptor antagonist, for the acute treatment of migraine. In Study 303, rimegepant Zydis ODT statistically differentiated from placebo on the two co-primary endpoints as well as the first 21 consecutive primary and secondary outcome measures that were prespecified in hierarchical testing.
Benzinga4 months ago
The Daily Biotech Pulse: Twist In Protagonist Tale, Catalyst's Autoimmune Disorder Drug Approved
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 28) Merck & Co., Inc. (NYSE: MRK ) Ionis Pharmaceuticals ...
PR Newswire4 months ago
Biohaven Announces Formation Of BioShin, A Wholly Owned Asia-Pacific Subsidiary
NEW HAVEN, Conn. and SHANGHAI, Nov. 28, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) announced today that it has advanced the formation of a wholly owned subsidiary, BioShin™, a Shanghai based limited liability company, to develop and commercialize its late-stage migraine and neurology portfolio in China and other Asia-Pacific markets. Biohaven's Chief of Corporate Strategy and Business Development, Donnie McGrath, M.D., has been appointed Chief Executive Officer of the new subsidiary which will be based in Shanghai. Previously, Dr. McGrath was Vice-President of Business Development and Head of Global Search and Evaluation at Bristol-Myers Squibb (BMS).
GlobeNewswire4 months ago
Factors of Influence in 2018, Key Indicators and Opportunity within Dillard's, Biohaven Pharmaceutical Holding, HTG Molecular Diagnostics, Strongbridge Biopharma, Myriad Genetics, and Beazer Homes — New Research Emphasizes Economic Growth
NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
PR Newswire4 months ago
Biohaven Announces FDA Acceptance of 505(b)(2) NDA Filing for BHV-0223, a Novel Sublingual Delivery Form of Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
NEW HAVEN, Conn., Nov. 26, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) today announced that its 505(b)(2) new drug application (NDA) for BHV-0223, an investigational sublingual form of riluzole for the treatment of people living with amyotrophic lateral sclerosis (ALS), has been accepted for review by the U.S. Food and Drug Administration (FDA). Biohaven previously announced that the FDA granted orphan drug designation for BHV-0223 in ALS. BHV-0223 is a novel, lower dose formulation of riluzole designed to be placed under the tongue where it dissolves in seconds and is absorbed sublingually.
PR Newswire4 months ago
Biohaven Pharmaceuticals to Host Inaugural Research & Development Day on November 26, 2018
- Three panels with 13 KOLs highlighting migraine, glutamate and inflammation platforms NEW HAVEN, Conn. , Nov. 20, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biotechnology ...